6-(p-Chlorophenyl)-4,5-dihydro-5-methyl-3-(2H)pyridazinon | 36725-41-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-(p-Chlorophenyl)-4,5-dihydro-5-methyl-3-(2H)pyridazinon
• 英文别名: 6-(4-chloro-phenyl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one；6-(4-Chlorophenyl)-5-methyl-2,3,4,5-tetrahydropyridazin-3-one；3-(4-chlorophenyl)-4-methyl-4,5-dihydro-1H-pyridazin-6-one
• CAS: 36725-41-4
• 化学式: C₁₁H₁₁ClN₂O
• mdl: MFCD00187265
• 分子量: 222.674
• InChiKey: VECYAKYVLADWSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
  申请人：THE BROAD INSTITUTE, INC.

  公开号：US20160016913A1

  公开（公告）日：2016-01-21

  Disclosed are compounds, such as pyridazinones, that can be, inter alia, used for treating cancer.

  本发明涉及一些化合物，例如吡啶并咪唑酮，可用于治疗癌症等疾病。
• Compositions and methods for inhibiting platelet activation and thrombosis
  申请人：Flaumenhaft Charles Robert

  公开号：US20070060605A1

  公开（公告）日：2007-03-15

  The invention provides methods and compositions for reducing platelet activation, platelet aggregation and thrombosis. The invention further provides compositions and methods for treating or preventing diseases or disorders in which the pathology of the disease or disorder involves one or more of platelet activation, platelet aggregation and thrombus formation. The invention additionally relates to the use of protein palmitoylation inhibitors for the reduction of platelet activation, platelet aggregation and thrombosis, as well as to the use of protein palmitoylation as a target for the identification of inhibitors of platelet activation, platelet aggregation and thrombosis.
• US3931176A
  申请人：——

  公开号：US3931176A

  公开（公告）日：1976-01-06
• US4055644A
  申请人：——

  公开号：US4055644A

  公开（公告）日：1977-10-25
• US4136184A
  申请人：——

  公开号：US4136184A

  公开（公告）日：1979-01-23